MarketCap
Facebook
X
TelegramAphria Inc. General and Administrative Expenses 2011-2026 | APHA
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Aphria Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 164 M | 124 M | 43.6 M | 7.08 M | 2.89 M | 6.62 M | 124 K | 47.8 K | 97.8 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 164 M | 47.8 K | 38.7 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 9.13 | -0.76 % | $ 591 M |  USA |
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.91 | 2.42 % | $ 6.69 M | China |
 |
Edesa Biotech
EDSA
|
4.13 M | $ 15.52 | -2.39 % | $ 49.6 M | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 22.47 | 1.19 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Fortress Biotech
FBIO
|
96.4 M | $ 2.24 | 0.9 % | $ 62.5 M | USA |
 |
Galectin Therapeutics
GALT
|
5.8 M | $ 2.26 | 0.22 % | $ 144 M | USA |
 |
Galapagos NV
GLPG
|
141 M | $ 28.07 | 0.75 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
1.06 B | $ 8.2 | 3.6 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
153 M | $ 31.01 | -0.13 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
3.2 M | $ 8.44 | - | $ 76.2 M | USA |
 |
InflaRx N.V.
IFRX
|
12 M | $ 1.95 | -1.77 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
3.52 M | $ 0.83 | 3.44 % | $ 6.55 M |  Australia |
 |
Incyte Corporation
INCY
|
1.38 B | $ 98.87 | -0.23 % | $ 19.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
369 K | $ 0.71 | 1.28 % | $ 1.74 M |  Canada |
 |
INmune Bio
INMB
|
10.3 M | $ 1.35 | 1.5 % | $ 33.4 M | USA |
 |
Innoviva
INVA
|
113 M | $ 23.13 | 0.35 % | $ 1.56 B | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
5.78 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 104.54 | 2.92 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Jaguar Health
JAGX
|
18.6 M | $ 7.55 | -4.13 % | $ 17.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
125 M | $ 26.67 | -0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
25.5 M | $ 1.43 | -4.03 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
12.6 M | $ 8.15 | 0.49 % | $ 260 M |  Israel |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
4.51 M | $ 13.24 | 6.56 % | $ 1.75 B | Australia |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
78.7 M | $ 223.98 | -0.39 % | $ 4.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.22 | 7.69 % | $ 5.3 M | Israel |
 |
Liquidia Corporation
LQDA
|
157 M | $ 38.39 | 0.62 % | $ 3.3 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.08 | 0.74 % | $ 436 M | USA |